Floatz logo

Irinotecan

Neuroendocrine Neoplasm

First Affiliated Hospital Xi'an Jiaotong UniversitySmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Surufatinib
Shanghai Changzheng Hospital
Phase 3BB
Oxodotreotide
Fundación de investigación HM
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →